After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%.

老虎证券2026/07/07 14:54

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This key regulatory development has significantly shortened the drug review timeline, paving the way for potential accelerated market launch and sparking a positive market reaction. The strong rise in the company's stock price reflects increased investor confidence in the commercial prospects of this innovative therapy, as well as a revaluation of the company's R&D pipeline.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%.

You may also like

Crypto prices